- Home
- ADIL vs MBRX Comparison
ADIL vs MBRX Comparison
Compare ADIL & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- MBRX
- Stock Information
- Founded
- ADIL 2010
- MBRX 2015
- Country
- ADIL United States
- MBRX United States
- Employees
- ADIL N/A
- MBRX N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- MBRX Health Care
- Exchange
- ADIL Nasdaq
- MBRX Nasdaq
- Market Cap
- ADIL 4.3M
- MBRX 4.4M
- IPO Year
- ADIL 2018
- MBRX 2016
- Fundamental
- Price
- ADIL $0.62
- MBRX $0.80
- Analyst Decision
- ADIL Strong Buy
- MBRX Strong Buy
- Analyst Count
- ADIL 1
- MBRX 3
- Target Price
- ADIL $8.00
- MBRX $17.33
- AVG Volume (30 Days)
- ADIL 72.0K
- MBRX 640.3K
- Earning Date
- ADIL 05-13-2025
- MBRX 05-09-2025
- Dividend Yield
- ADIL N/A
- MBRX N/A
- EPS Growth
- ADIL N/A
- MBRX N/A
- EPS
- ADIL N/A
- MBRX N/A
- Revenue
- ADIL N/A
- MBRX N/A
- Revenue This Year
- ADIL N/A
- MBRX N/A
- Revenue Next Year
- ADIL N/A
- MBRX N/A
- P/E Ratio
- ADIL N/A
- MBRX N/A
- Revenue Growth
- ADIL N/A
- MBRX N/A
- 52 Week Low
- ADIL $0.61
- MBRX $0.40
- 52 Week High
- ADIL $3.10
- MBRX $5.91
- Technical
- Relative Strength Index (RSI)
- ADIL 36.45
- MBRX 34.26
- Support Level
- ADIL $0.67
- MBRX $0.92
- Resistance Level
- ADIL $0.72
- MBRX $1.04
- Average True Range (ATR)
- ADIL 0.05
- MBRX 0.10
- MACD
- ADIL -0.00
- MBRX -0.02
- Stochastic Oscillator
- ADIL 0.00
- MBRX 9.07
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.